Cytisine treatment for helping smokers quit and its effects on heart health
The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers of Conventional Combustible Cigarettes and New Tobacco Products-Observational Study.
This study tests if a plant-based treatment called cytisine can help adult smokers quit and also looks at how it affects their heart health during and after the treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University of Athens Academic / other |
| Locations | 1 site (Athens, Haidari) |
| Trial ID | NCT06885970 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of cytisine, a plant-derived alkaloid, in aiding smoking cessation among adult smokers and users of alternative nicotine products. The study focuses on a 25-day treatment regimen and assesses its impact on cardiovascular function, including arterial stiffness and endothelial health. Additionally, it aims to track relapse rates, treatment side effects, and any new cardiovascular events during and after the treatment period. Participants will be recruited from a smoking cessation unit at a cardiology department.
Who should consider this trial
Good fit: Ideal candidates are adult smokers or users of alternative nicotine products who are willing to participate in the study.
Not a fit: Patients with a history of coronary artery disease, active malignancy, severe liver or renal failure, or autoimmune diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve smoking cessation rates and cardiovascular health in smokers.
How similar studies have performed: Previous studies have shown promising results with similar pharmacological approaches for smoking cessation, suggesting potential for success in this study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Smokers willing to participate Exclusion Criteria: * history of coronary artery disease, active malignancy, history of severe liver and renal failure, history of autoimmune disease.
Where this trial is running
Athens, Haidari
- Attikkon University Hospital — Athens, Haidari, Greece (Recruiting)
Study contacts
- Study coordinator: Ignatios Ikonomidis, MD;PhD
- Email: ignoik@gmail.com
- Phone: 00306944805732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.